Figure 3From: Agalsidase alfa in pediatric patients with Fabry disease: a 6.5-year open-label follow-up studyLeft ventricular mass indexed to height (LVMI; g/m 2.7) over time in the transition safety population. (a) Individual patients and (b) mean (± SD) change from baseline; the dotted line represents the annualized slope. Baseline mean ± SD LVMI values at the beginning of phase 1 were 30.66 ± 5.96 g/m2.7 (measured at study TKT023 week 25/26). Agalα, agalsidase alfa; CI, confidence interval; LVMI, left ventricular mass index; SD, standard deviation; ULN, upper limit of normal.Back to article page